Nov 20

LAM to Present Data Demonstrating Efficacy of DNA Methylation as Epigenetic Biomarkers for Non-Invasive Breast Cancer Detection at Upcoming San Antonio Breast Cancer Symposium

Presentation showcases ability of blood-based DNA methylation to diagnose disease with high specificity and sensitivity

IRVINE, Calif., Nov. 20, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the 2018 San Antonio Breast Cancer Symposium taking place Dec. 4 – 8 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This presentation will include new data supporting the ability of LAM’s IvyGene Platform to detect blood-based DNA methylation biomarkers for the non-invasive diagnosis of breast cancer with high specificity and sensitivity. The data will be presented in the Detection/Diagnosis: Circulating BioMarkers & ctDNA poster session on December 7 from 7:30 a.m. – 9:00 a.m. CST.
Presentation Information:
Title: “Blood-based DNA Methylation as Epigenetic Biomarkers for Non-invasive Detection of Breast                   Cancer”
Authors: Dhruvajyoti Roy, Lianghong Zheng, Dan Liu, Gen Li, Mingzhen Li, Richard A. Van Etten
Session Date: Friday, December 7
Session Time: 7:30 a.m. – 9:00 a.m. CST
DNA methylation significantly contributes to all hallmarks of cancer. In particular, promoter hypermethylation has been identified as a potential marker for early detection of cancer, therapy monitoring, assessment of prognosis or prediction of therapy response. Here, we identified and validated breast cancer-specific methylation markers for diagnosis of the disease with high sensitivity and specificity.
For more information on the Symposium, please visit:
About Laboratory for Advanced Medicine
LAM is a commercial-stage medical technology company focused on developing innovative, noninvasive, nontoxic technologies for the early diagnosis and intervention of cancers, possibly years before current technology can detect. The company is dedicated to building and growing world-class technologies from the laboratory to the clinic.
Headquartered in the United States with offices in California, Texas and Indiana, LAM has collaborations with leading scientists, physicians, research institutions and business leaders in the U.S. and China, combining their experiences to provide the most effective and safest diagnostic technologies to patients and their doctors. The company has CLIA-registered and CAP-accredited as well as third-party laboratories and cGMP facilities all working toward bringing first-class technologies to the medical community today.
Media Contacts:
Russo Partners
Caroline Cunningham or Alex Fudukidis
Tel: (212) 845-4292 / (646) 942-5632